Hepion Pharmaceuticals (HEPA) chair LoPriore reports 20M-share and warrant purchases
Rhea-AI Filing Summary
Hepion Pharmaceuticals Executive Chairman Vincent S. LoPriore, through entities he controls, reported purchases totaling 20,000,000 HEPA-related securities on August 3, 2026. Gravitas Capital LP and Invictus Capital Advisors Pension Plan bought 10,000,000 warrants with a $0.06 exercise price and 10,000,000 common shares at $0.05 per share, all held as indirect ownership.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 10,000,000 shares
Net Buy
4 txns
Insider
LoPriore Vincent S
Role
Executive Chairman
Bought
20,000,000 shs ($500K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants F1 | 8,000,000 | $0.00 | $0.00 |
| Purchase | Warrants F2 | 2,000,000 | $0.00 | $0.00 |
| Purchase | Common Stock F1 | 8,000,000 | $0.05 | $400K |
| Purchase | Common Stock F2 | 2,000,000 | $0.05 | $100K |
Holdings After Transaction:
Warrants — 8,000,000 shares (Indirect, By Gravitas Capital LP);
Warrants — 10,000,000 shares (Indirect, By Invictus Capital Advisors Pension Plan);
Common Stock — 14,250,000 shares (Indirect, By Gravitas Capital LP);
Common Stock — 16,250,000 shares (Indirect, By Invictus Capital Advisors Pension Plan)
Footnotes (2)
- F1. Mr. LoPriore is the Managing Member of Gravitas Capital LP and in such capacity has the right to vote and dispose of the securities held by such entity.
- F2. Mr. LoPriore is the trustee and beneficiary of the Invictus Capital Advisors Pension Plan and in such capacity has the right to vote and dispose of the securities held by such entity.
Key Figures
Warrants purchased via Gravitas: 8,000,000 warrants
Warrants purchased via Invictus Plan: 2,000,000 warrants
Warrant exercise price: $0.06 per share
+5 more
8 metrics
Warrants purchased via Gravitas
8,000,000 warrants
Indirectly acquired on August 3, 2026 by Gravitas Capital LP
Warrants purchased via Invictus Plan
2,000,000 warrants
Indirectly acquired on August 3, 2026 by Invictus Capital Advisors Pension Plan
Warrant exercise price
$0.06 per share
Exercise price for all 10,000,000 warrants acquired
Warrant expiration
August 3, 2031
Expiration date for the acquired warrants
Common stock via Gravitas
8,000,000 shares
Indirectly purchased at $0.05 per share on August 3, 2026
Common stock via Invictus Plan
2,000,000 shares
Indirectly purchased at $0.05 per share on August 3, 2026
Post-transaction common holdings
16,250,000 shares
Total indirect common stock holdings after transactions
Total securities bought
20,000,000
Combined warrants and common stock acquired across all transactions
Key Terms
Warrants, indirect ownership, exercise price, dispositive power
4 terms
Warrants financial
"10,000,000 warrants with an exercise price of $0.06 per share"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
indirect ownership financial
"These securities are reported as indirect ownership through entities he controls"
exercise price financial
"Warrants carry an exercise price of $0.06 per share into common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
dispositive power financial
"He has the right to vote and dispose, reflecting dispositive power over securities"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
FAQ
What did Hepion Pharmaceuticals (HEPA) insider Vincent S. LoPriore purchase on August 3, 2026?
Vincent S. LoPriore reported purchasing 20,000,000 HEPA-related securities on August 3, 2026, including both warrants and common stock. The transactions were made through Gravitas Capital LP and Invictus Capital Advisors Pension Plan, which he controls and over which he has voting and dispositive power.
How many Hepion Pharmaceuticals (HEPA) warrants did Vincent S. LoPriore acquire and at what exercise price?
LoPriore indirectly acquired 10,000,000 warrants for Hepion Pharmaceuticals, each with an exercise price of $0.06 per share. These warrants are exercisable into common stock and have an expiration date of August 3, 2031, providing a long-dated derivative position.
What common stock purchases in Hepion Pharmaceuticals (HEPA) did Vincent S. LoPriore report?
He reported indirect purchases of 10,000,000 shares of common stock at a price of $0.05 per share. Eight million shares were held by Gravitas Capital LP and two million by Invictus Capital Advisors Pension Plan, both entities over which he has voting and dispositive authority.
Through which entities does Vincent S. LoPriore hold his Hepion Pharmaceuticals (HEPA) positions?
LoPriore holds these positions indirectly through Gravitas Capital LP and the Invictus Capital Advisors Pension Plan. As managing member or trustee and beneficiary, he has the right to vote and dispose of the securities held by each entity, according to the footnotes.
What are Vincent S. LoPriore’s reported indirect common stock holdings in Hepion Pharmaceuticals (HEPA) after these transactions?
After the reported purchases, LoPriore’s indirect holdings of common stock total 16,250,000 shares. This figure reflects the combined post-transaction position across Gravitas Capital LP and Invictus Capital Advisors Pension Plan as disclosed in the Form 4 data.
When do Vincent S. LoPriore’s newly acquired Hepion Pharmaceuticals (HEPA) warrants expire?
The newly acquired Hepion Pharmaceuticals warrants held indirectly by LoPriore expire on August 3, 2031. Each warrant carries an exercise price of $0.06 per share and is exercisable into Hepion common stock, providing long-term optionality on the shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
